Apixaban superior to aspirin in AVERROES

Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) reported that apixaban was superior to aspirin on the annual rate of the composite primary endpoint of stroke or systemic embolism in the Phase III AVERROES trial to treat atrial fibrillation (1.6% vs. 3.6%, p<0.001). On the primary safety endpoint, there was no significant difference in the annual rate of major hemorrhage between apixaban and aspirin. The double-blind, international trial enrolled 5,600 patients. Data were presented at the European Society of Cardiology meeting in Stockholm. ...